At Bio-Sourcing, we challenge ourselves to produce biologics for the veterinary market in a more cost-effective and scalable way than the conventional cell culture-based manufacturing platforms currently used for the manufacture of the majority of human biologics.
A short path to market: reduce the time to market of tailored biologics for the veterinary market to 4 to 6 years.
With Bio-Sourcing expertise, adapting a biological human drug to an efficient entity for use in an animal species is cleared in less than a year.
A production herd as small as forty animals can be established in less than 20 months. This will produce enough material for the global market of a single veterinary drug.
As the market develops, the overall flexibility of the set-up facilitates production scale-up to meet market demand, with little or no further investment.
Lower drastically your capital expenditure and your production costs.
Historically, the cost of developing and producing biologics has precluded their exploitation for animal health. Bio-Sourcing now offers a highly cost-effective manufacturing platform with tremendous flexibility.
The mammary gland can be considered as a protein factory yielding high expression of recombinant DNA-induced proteins both small and large, from peptidic hormones to large monoclonal antibodies.
Efficient, large-scale milk collection combined with high throughput chromatographic and filtration methods provide a high recovery yield with unrivaled production costs.
Method already approved for human therapeutics by the FDA and the EMA
Drugs produced in the milk of animals were approved as human therapeutics by the FDA in 2006 and by the EMA in 2009. By adapting this methodology for veterinary use, Bio-Sourcing will create an innovative and safe route for a number of applications.
Bio-Sourcing’s makes it possible for Animal Health companies to exploit its technology license from LFB to produce better and more affordable drugs.